BGC > Buscar Producto > Oxaliplatin

Molecular Formula: C6H14N2.C2O4.Pt
Molecular Weight: 397,29

Description:
Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy that inhibits DNA synthesis by conforming DNA adducts in cancer cells.

• Molecular Weight:397.29
• Melting Point:>196°C (dec.)
• Purity:>98%

Molecular Formula:
C8H14N2O4Pt
Canonical SMILES:
O=C1[O-][Pt+2]2([O-]C1=O)[NH2]C3CCCCC3[NH2]2
InChI:
InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
InChIKey:
ZROHGHOFXNOHSO-BNTLRKBRSA-L
Solubility:
Soluble in DMSO (Sparingly), Methanol (Very Slightly), Water (Slightly)
Appearance:
White to Off-white Solid
Storage: Store at -20°C
Synonyms:
Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]-, (SP-4-2)-; (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum; 1,2-Cyclohexanediamine, platinum complex, (1R-trans)-; Platinum, (1,2-cyclohexanediamine-N,N')[ethanedioato(2-)-O,O']-, [SP-4-2-(1R-trans)]-; Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN,κN'][ethanedioato(2-)-κO1,κO2]-, (SP-4-2)-; Dacplat; Eloxatin; Elplat; l-OHP; Lipoxal; NSC 266046; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); Oxalato[trans-(-)-1,2-cyclohexanediamine]platinum(II); Oxalatoplatin; Oxalatoplatinum; Platinum, (1,2-cyclohexanediamine-κN,κN')[ethanedioato(2-)-κO1,κO2]-, [SP-4-2-(1R-trans)]-; RP 54780; trans-L-Diaminocyclohexane oxalatoplatinum

Purity: 98%
Smile code: O=C1O[Pt]2([NH2][C@@H]3CCCC[C@H]3[NH2]2)OC1=O
MDL Number: MFCD00866327
MolFormula: C8H14N2O4Pt
MolWeight: 397.2858
Available in stock: 49.393

OXALIPLATIN is an enantiomerically pure platinum-based antineoplastic agent (inhibition of cell proliferation) used in cancer chemotherapy.
THERAPEUTIC INDICATION: ONCOLOGY

OXALIPLATIN is used for the treatment of colorectal cancer, typically along with Folinic acid and 5-fluorouracil in a combination known as FOLFOX. It has been compared to other Pt- compounds used for advanced cancers, such as Cisplatin and Carboplatin. A combination with the mono-clonal antibody Bevacizumab increases its activity.

MARKET INFORMATION
Originator: SANOFI-AVENTIS
Originator product: ELOXATIN®

YOUR ADVANTAGES

- Manufactured in China by a reliable supplier
- Good quality product with matching EP & JP quality
- USP is based on a different process